About this Journal Submit a Manuscript Table of Contents
ISRN Rheumatology
Volume 2014 (2014), Article ID 348726, 13 pages
http://dx.doi.org/10.1155/2014/348726
Review Article

Review on Effectiveness of Primary Prophylaxis in aPLs with and without Risk Factors for Thrombosis: Efficacy and Safety

1King Abdullah Medical Complex-Jeddah (KAMCJ), Al-Ameer Nayef Street, North Obhur, P.O. Box 55659, Jeddah 21544, Saudi Arabia
2Department of Medicine, Rheumatology Section, Hamad Medical Corporation, P.O. Box 3050, Off Al Rayyan Road, Opposite Lulu Center, Doha, Qatar

Received 9 January 2014; Accepted 10 February 2014; Published 17 April 2014

Academic Editors: E. F. Borba, P. A. Gatenby, and T. Kawakami

Copyright © 2014 Nahid A. Qushmaq and Samar A. Al-Emadi. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Context. Antiphospholipid antibodies syndrome is an autoimmune disorder that is characterized by the association between presence of antiphospholipid antibodies and risk of thrombosis and/or pregnancy morbidity. Objectives. To systematically review the evidence for primary prophylaxis in patients with antiphospholipids antibodies syndrome or APS with or without other traditional risk factors of thrombosis when they did not have any thrombotic event yet. Methods. PubMed, the Cochrane Library, and Allied Health Literature were searched for studies that examined the efficacy and safety of primary prophylaxis in aPL patients from 1990 to February 2013. We examined literature looking at patients with aPLs with other risk factors for thrombosis and aPLs with no additional risk factors for thrombosis. Conclusion. We concluded that, in patients with aPLs, primary prophylaxes with HCQ and aspirin have been observed to reduce the frequency of thrombotic events in the case of asymptomatic aPL-positive patients with SLE. We also in this study concluded that LDA was effective in patients with autoimmune diseases. Independent cardiovascular risk factors include autoimmune defects such as SLE, rheumatoid arthritis, and atherosclerosis, where overall venous thrombosis will be induced by systemic inflammation. This review concludes that HCQ is an effective primary approach when compared to aspirin.